Reading CTOR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CTOR free→Reading CTOR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CTOR free→QuarterlyIQ Insights · CTOR
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 15, 2026, Citius Oncology, Inc. (the “Company,” “we,” or “our”) issued a press release announcing our results of operations for the second quarter of fiscal 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth under
Entry into a Material Definitive Agreement. Warrant Inducement Transaction On May 5, 2026, Citius Oncology, Inc. (the “Company”), entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with the holder of certain existing warrants to purchase up to an aggregate of 12,777,778 shares of the Company’s common stock, which consists of all of the 6,818,182 shares underlying warrants originally issued on July 16, 2025, all of the 5,142,858 shares underlying warrants original…
The securities described above will be offered and sold in reliance upon an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The issuance of the New Warrants, the Placement Agent Warrants, the Loan Agreement, the Lender Warrants and any shares of common stock issuable thereunder have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent regist…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On April 22, 2026, Nasdaq Stock Market LLC (“Nasdaq”) notified Citius Oncology, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasda…
Results of Operations and Financial Condition. On February 13, 2026, Citius Oncology, Inc. (the “Company,” “we,” or “our”) issued a press release announcing our results of operations for the first quarter of fiscal 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exch…
Results of Operations and Financial Condition. On December 23, 2025, we issued a press release announcing our results of operations for the full year of fiscal 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of t…
Entry into a Material Definitive Agreement. On December 8, 2025, Citius Oncology, Inc. (the “Company”) entered into a securities purchase agreement (the “RD Purchase Agreement”) with a certain institutional investor in a registered direct offering for the purchase and sale of 1,284,404 shares of our common stock, $0.0001 par value per share, at an offering price of $1.09 per share of common stock (the “Shares”). In a concurrent private placement, the Company also agreed to sell such instituti…
Unregistered Sales of Equity Securities. The information contained in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 27, 2025, Citius Oncology, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, stockholders of the Company approved an amendment to the Company’s 2024 Omnibus Stock Incentive Plan (the “Amendment”) increasing the number of shares of the Company’s common stock authorized for iss…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 19, 2025, the board of directors of the Company approved an amendment to the Company’s 2024 Omnibus Stock Incentive Plan (the “2024 Plan”) to increase the authorized number of shares of the Company’s common stock reserved for issuance thereunder from an aggregate of 15,000,000 shares to an aggregate of 30,000,000 shares. Other than the…
Unregistered Sales of Equity Securities. On September 19, 2025, Citius Oncology, Inc. (the “Company) issued to a financial advisor warrants to purchase up to 360,000 shares of our common stock with an exercise price of $2.1875 per shares, that are exercisable on March 10, 2026, and that expire on March 10, 2031. The warrants were issued in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.
The issuance of the Warrants was not registered under the Securities Act or any state securities laws. The issuance of the Warrants will be in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder.
Entry into a Material Definitive Agreement. On September 9, 2025, Citius Oncology, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with a certain purchaser for the purchase and sale, in a “best-efforts” registered direct offering by the Company, of 5,142,858 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”)…
Other Events. Citius Oncology, Inc. today filed a prospectus supplement to its registration statement on Form S-1 that was declared effective on July 15, 2025, pursuant to which it sold common stock and warrants in a public offering on July 17, 2025. The prospectus supplement is necessary to keep the registration statement current with Citius Oncology’s recently filed Quarterly Report on Form 10-Q because Citius Oncology is not yet eligible to incorporate by reference into the Form S-1 regist…
Results of Operations and Financial Condition. On August 12, 2025, we issued a press release announcing our results of operations for the third quarter of fiscal 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of…
Entry into a Material Definitive Agreement. On July 16, 2025, Citius Oncology, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with a certain purchaser for the purchase and sale, in a “best-efforts” public offering by the Company (the “Public Offering”), of 6,818,182 shares of the Company’s common stock, par value $0.0001 per share (the…
Results of Operations and Financial Condition. On May 14, 2025, we issued a press release announcing our results of operations for the second quarter of fiscal 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of t…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On April 23, 2025, Nasdaq Stock Market LLC (“Nasdaq”) notified Citius Oncology, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasda…
Entry into a Material Definitive Agreement. As previously reported, in September 2021, Citius Pharmaceuticals, Inc. (“Citius Pharma”), which owns approximately 92% of the outstanding common stock of Citius Oncology, Inc. (“Citius Oncology”), announced that it had entered into an asset purchase agreement with Dr. Reddy’s Laboratories SA (“Dr. Reddy’s”) to acquire its exclusive license of E7777 (denileukin diftitox). Dr. Reddy’s had previously exclusively licensed E777 in select markets from Ei…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.